ImageneBio, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
IMA$3.81-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(10,619) | $(6,077) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 876 | 57 |
| Amortization of right-of-use assets | 174 | 78 |
| Accretion of discounts on marketable securities, net | (7) | — |
| Non-cash interest expense | — | 118 |
| Depreciation and amortization expense | — | 2 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 141 | (1,793) |
| Deposits and other non-current assets | (3,452) | — |
| Accounts payable | (871) | 1,425 |
| Accrued expenses and other current liabilities | (494) | (306) |
| Deferred revenue | — | (650) |
| Other non-current liabilities | 11 | — |
| Operating lease liabilities | (559) | (84) |
| Net cash used in operating activities | (14,800) | (7,230) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (10,937) | — |
| Maturities of marketable securities | 10,497 | — |
| Net cash used in investing activities | (440) | — |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 35 | 45 |
| Payment of issuance costs in connection with reverse recapitalization | (3,279) | — |
| Payment of deferred offering costs | — | (18) |
| Net cash provided by (used in) financing activities | (3,244) | 27 |
| Effect of exchange rate changes on cash and cash equivalents | — | 3 |
| Net change in cash and cash equivalents | (18,484) | (7,200) |
| Cash and cash equivalents at beginning of period | 94,532 | 12,118 |
| Cash and cash equivalents at end of period | $76,048 | $4,918 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Accretion of redeemable convertible preferred shares | $— | $3,051 |
| Deferred offering costs included in accounts payable and accrued expenses and other current liabilities | $— | $3,602 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.